Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Market Closed -
Euronext Paris
19:55:00 11/11/2026 +03
|
Pre-market 10:40:41 | |||
| 226.80 EUR | +1.52% |
|
226.40 | -0.18% |
| 10-26 | Sartorius Stedim Biotech : Jefferies reiterates its Buy rating | ZD |
| 10-23 | Sartorius Stedim Biotech : JP Morgan maintains a Buy rating | ZD |
| Market Cap | 22.07B 24.48B 20.39B 18.43B 34.87B 2,296B 35.73B 244B 97.38B 1,230B 91.89B 89.93B 3,914B | P/E 2026 * |
57.7x | P/E 2027 * | 44.1x |
|---|---|---|---|---|---|
| Enterprise Value | 24.06B 26.7B 22.23B 20.1B 38.02B 2,504B 38.96B 266B 106B 1,341B 100B 98.06B 4,267B | EV / Sales 2026 * |
7.68x | EV / Sales 2027 * | 6.83x |
| Free-Float |
28.47% | Yield 2026 * |
0.36% | Yield 2027 * | 0.44% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
CBOE
| 0NK7 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
Xetra
| 56S1 | Delayed | |
|
OTC Markets
| SDMHF | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +1.52% | ||
| 1 week | +1.43% | ||
| Current month | +1.52% | ||
| 1 month | +6.58% | ||
| 3 months | +25.72% | ||
| 6 months | +38.04% | ||
| Current year | +8.00% |
| 1 week | 218 |  | 229.8 |
| 1 month | 208 | | 229.8 |
| Current year | 150 | | 229.8 |
| 1 year | 150 | | 229.8 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 62 | 08/09/2011 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 70 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 69 | 14/09/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 A | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 A | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 A | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.52% | +1.43% | +17.76% | +22.59% | 24.48B | |
| -1.06% | -5.38% | -13.94% | +16.30% | 189B | |
| +0.02% | -3.19% | +6.51% | +43.76% | 124B | |
| -1.70% | -6.14% | -12.35% | +16.51% | 121B | |
| -2.69% | -3.46% | -42.12% | +4.37% | 93.09B | |
| +0.34% | -1.16% | -4.16% | +77.09% | 66.77B | |
| +0.90% | +2.55% | +13.49% | -8.58% | 58.43B | |
| +0.85% | +0.58% | -1.39% | +63.88% | 55.35B | |
| +0.96% | +0.06% | -1.73% | +56.33% | 49.49B | |
| -3.88% | -6.01% | -3.60% | -8.41% | 34.53B | |
| Average | -0.47% | -1.95% | -4.15% | +28.38% | 82B | |
| Weighted average by Cap. | -0.71% | -2.97% | -8.07% | +27.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.48B 2.89B 2.62B 4.95B 326B 5.07B 34.69B 13.83B 175B 13.05B 12.77B 556B | 3.48B 3.87B 3.22B 2.91B 5.51B 363B 5.64B 38.58B 15.38B 194B 14.51B 14.2B 618B |
| Net income | 384M 426M 355M 321M 607M 39.95B 622M 4.25B 1.69B 21.4B 1.6B 1.56B 68.1B | 489M 543M 452M 409M 773M 50.92B 792M 5.42B 2.16B 27.27B 2.04B 1.99B 86.78B |
| Net Debt | 1.99B 2.21B 1.84B 1.67B 3.15B 208B 3.23B 22.08B 8.8B 111B 8.31B 8.13B 354B | 1.74B 1.93B 1.61B 1.46B 2.75B 181B 2.82B 19.3B 7.69B 97.16B 7.26B 7.11B 309B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/11/26 | €226.80 | +1.52% | 71,742 |
| 10/11/26 | €223.40 | -1.24% | 86,541 |
| 09/11/26 | €226.20 | +0.18% | 76,715 |
| 06/11/26 | €225.80 | +0.71% | 105,334 |
| 05/11/26 | €224.20 | +0.27% | 104,689 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
